Concerned with Pfizer's marketing of Viagra, the AIDS Healthcare Foundation (AHF), the largest AIDS healthcare provider in the U.S., has banned the company's sales representatives from its facilities.

The healthcare advocacy group Community Catalyst has begun what it says is the first comprehensive campaign to conduct and publicize research on potential conflicts of interest arising from the $12 billion spent annually on pharmaceutical marketing directed at physicians.

Australia's Therapeutic Goods Administration and New Zealand's Medicines and Medical Devices Safety Authority have issued a draft rule on advertising of therapeutic products.

The Centers for Medicare & Medicaid Services (CMS) must strengthen its guidance regarding an exception to Medicaid price-reporting requirements to prevent drug companies' abuse of that provision, key lawmakers say.

The Washington Legal Foundation (WLF) is supporting a former regulatory affairs official's appeal of a recent court ruling that he conspired to sell a device that had not been approved by the FDA.

An HIV/AIDS healthcare provider has filed a lawsuit against Pfizer, saying its marketing campaign for Viagra promoted recreational use of the drug and contributed to increased incidence of sexually transmitted diseases (STDs), including HIV.

An analysis of 84 studies by HHS' Agency for Healthcare Research and Quality (AHRQ) found no strong evidence that atypical antipsychotics are effective for many of the off-label uses for which they are commonly prescribed.

The "art and science" of branding -- developing name and image recognition for a particular product and company -- is still in the developmental stages in the device industry, according to Nancy Turett, president of the health division at the public relations firm Edelman.

Medtronic has launched a national print, television and online advertising campaign to raise awareness of sudden cardiac arrest (SCA), its risk factors and the role of implantable cardioverter-defibrillator (ICD) therapy, the firm said Jan. 15.

Improved drug safety is foremost in the FDA's Prescription Drug User Fee Act (PDUFA) proposal that seeks new authority and more than $29 million in additional fees specifically to improve its postmarket safety surveillance.